Drug development
Eledon Pharmaceuticals develops antibody medicines that aim to calm the immune system, with tegoprubart as its main product candidate for transplant patients and certain autoimmune conditions.
Customers and revenue model
Eledon Pharmaceuticals Inc
F:2TK
Eledon Pharmaceuticals Inc
F:2TK
Price:
1.92
EUR
-4%
Market Closed
Market Cap:
€73.9m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Eledon Pharmaceuticals Inc
F:2TK
|
US |
|
V
|
Vicem But Son Cement JSC
VN:BTS
|
VN |
|
B
|
Bloomios Inc
OTC:BLMS
|
US |
|
Euronext Athens Holding SA
F:HEE
|
GR |
|
Cookpad Inc
TSE:2193
|
JP |
|
P
|
PetroVietnam Power Engineering Consulting JSC
VN:PPE
|
VN |
|
Route 109 Resources Inc
F:8M0
|
CA |
|
T
|
Tintina Mines Ltd
XTSX:TTS
|
CA |
|
Elm Company SJSC
SAU:7203
|
SA |
|
Metals Exploration PLC
F:MJ4
|
UK |
|
P
|
PT Era Digital Media Tbk
IDX:AWAN
|
ID |
|
Dwi Guna Laksana Tbk PT
IDX:DWGL
|
ID |
|
F
|
First Paramount Modaraba
KAR:FPRM
|
PK |
|
G
|
Genflat Holdings Inc
OTC:GFLT
|
US |
Company Overview
Business Description
- Sector
- Health Care
- Industry
- Biotechnology
- Headquarters
- United States of America US
- Employees
- 33
- IPO date
- Sep 17, 2014
Eledon Pharmaceuticals is a clinical-stage drug company focused on medicines that calm the immune system. Its lead programs center on tegoprubart, an antibody designed to block a key immune signal called CD40L. The goal is to help patients who receive organ transplants or who live with autoimmune diseases by reducing harmful immune attacks without shutting the immune system down completely.
The company does not sell a broad portfolio of approved drugs. Instead, it develops and tests experimental therapies and then looks for partners or future approvals that could turn those medicines into products. Its main customers, if its drugs reach the market, would be transplant centers, hospitals, and physicians treating patients who need long-term immune suppression.
Eledon makes money today mainly through research and development activities tied to its drug pipeline, and in the future it would expect to earn product sales, licensing fees, or collaboration payments if any of its therapies succeed. What makes its business different is that it is trying to solve a very specific problem in transplant medicine: preventing rejection by targeting one immune pathway that could be less disruptive than older blanket immunosuppressive drugs.
Continue 2TK Research
Other Eledon Pharmaceuticals Inc listings: